Teradyne TER
Technology · Semiconductors · Synthos Deep Dive · 2026-07-03
The Overview
Teradyne makes the machines that test computer chips before those chips ship. Every advanced AI processor and memory stack has to be tested, and as AI chips get more complex, they need more (and more expensive) testing — that is the tailwind driving the business right now. Teradyne also owns a robotics arm (collaborative robots and warehouse robots).
The business is genuinely good: it is very profitable (keeps about 59 cents of gross profit per sales dollar), has more cash than debt, and its earnings are expected to roughly double next year. The catch: the stock has already tripled in the past year, so a lot of good news is baked in. At today's price you are paying about 49 times next year's expected profit — expensive — and this industry runs in boom-and-bust cycles, so the next down-leg can be brutal.
Our verdict is Watch: put it on the list, but the price today does not leave much cushion if the AI-test boom cools. Here is what our three scores mean in everyday terms:
- Downside Risk 7/10 (elevated). The balance sheet is safe, but the stock swings hard (high beta), the industry is cyclical, and the price is rich after a huge run.
- Growth Quality 7/10 (strong). Fast-growing and very profitable right now — but its history is lumpy, so "quality" comes with an asterisk.
- Exponential Potential 7/10 (high). Growth is genuinely speeding up, which is rare and valuable — just remember it is a cycle that can turn.
The one big worry: this is a cyclical, customer-concentrated business (a lot of revenue flows through a handful of big Asian chipmakers). If AI-chip test demand cools even for a couple of quarters, both the earnings and the rich multiple can fall at the same time.
Putting a number on it: our fair-value estimate is $400 against a current price of $354.97 — real upside if our numbers are right.
Our summary metrics
Net-cash balance sheet, but beta 1.79, cyclical semi-cap, 49× FY26E after a 3× 12-mo run.
FY26E revenue +42% / EPS +114% on AI-test demand, 59% GM, 30% ROE — but historically lumpy/cyclical.
Growth is genuinely accelerating (2nd derivative positive) off AI-compute test — but it is a cycle, not a secular line.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Growth is genuinely accelerating (2nd derivative positive) off AI-compute test — but it is a cycle, not a secular line.
“Teradyne's Q2 was its most important earnings call in years — AI inflection plus TAM expansion into merchant GPU testing (a market ~2x larger); bull case much stronger and chart pattern scores a buy.”
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $385.73 (high $550 / low $220; 20 Buy · 11 Hold · 0 Sell) — context, not our anchor |
| Valuation | ~68× trailing EPS · ~49× FY26E · ~36× FY27E · ~27× FY28E · EV/S 15.2× · EV/EBITDA 52× TTM |
| Technicals | Mixed — $369, −24% off the 52-wk high, above 200-DMA but below 50-DMA, RSI 48, +302% 12-mo (SPY +21%) |
| Conviction | Low — 1 net-bullish voice (Jordi Visser, skill 2.0, conviction 65), 1 reconciled claim; not a breadth call |
| Position sizing | Satellite-only if at all, ≤1–2%, scale on cyclical pullbacks — not a core holding |
What the experts actually said 8 traceable claims on TER · showing the highest-conviction voices
“Teradyne is a favorite name that hadn't yet performed, shifting from mobile weakness to AI/computing growth — moving from ~130 toward 200 for a double, not there yet.”
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $354.97, 7% below the 50-day average ($382), 14% above the 200-day average ($312) — a mixed trend. 27% below the 52-week high of $484, 216% above the 52-week low of $112.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $354.97 is currently inside the band (band $342–$429).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 44.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 4.52, negative momentum.
Relative performance vs S&P 500 & its sector (XLK (sector)), set to 100 a year ago
Solid = TER · dashed = S&P 500 · dotted = XLK (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Teradyne (NASDAQ: TER), founded 1960, headquartered in North Reading, MA, is a global leader in automated test equipment (ATE) — the systems that test semiconductors at wafer and packaged-device stages — plus an industrial-automation (robotics) arm. It reports across four lines:
1. Semiconductor Test — the core: FLEX, J750, Magnum (memory), ETS (analog/mixed-signal) platforms serving IDMs, fabless designers, foundries, and OSATs (outsourced assembly/test).
2. System Test — defense/aerospace instrumentation, storage test, PCB inspection.
3. Industrial Automation — Universal Robots (collaborative arms) and MiR (autonomous mobile robots).
4. Wireless Test — the LitePoint brand (Wi-Fi, 5G, connectivity test).
Fiscal year ends late December. CEO Gregory Smith. ~6,500 employees.
Revenue mix (FY2025, from FMP segmentation):
- By type: Product $2.66B (83%) · Service $0.53B (17%). Recurring service revenue is a stabilizer against the lumpier equipment cycle.
- By geography (FY25): Taiwan $1.16B (36%) · Korea $446M · China $451M · United States $361M · EMEA $215M · rest of Asia (Malaysia, Philippines, Singapore, Thailand) + RoW the balance. This is a heavily Asia-concentrated, foundry/OSAT-driven revenue base — Taiwan alone is over a third, which is both where the leading-edge test demand is and a real geopolitical/concentration exposure (§11). US end-demand is only ~11% of billings.
The forward story the numbers tell: after a soft 2023–24 (revenue troughed vs the 2021 peak of $3.70B), Teradyne is inflecting hard on AI-compute SoC and high-bandwidth-memory (HBM) test intensity — the FY26E revenue jump to ~$4.54B (+42% estimated) is the whole bull case.
2. The expert thesis — thin coverage, fundamentals-driven (traceable)
Honest disclosure: expert coverage in the Synthos KB is thin. There is 1 traceable claim (total_claims = 1), so this is not a breadth-conviction name — the verdict below is fundamentals- and quant-driven, not panel-driven.
- The one voice is Jordi Visser (selection skill 2.0 — our highest-skill tier), bullish, conviction 65 (
jordi_visser_m-jJvVd29aY-4:bd3baee54f, 2026-02-05): "Analog-based semiconductor names like Teradyne and Lattice haven't participated yet and have a long road ahead." This is a catch-up / long-runway call, categorized under analog and semiconductors. It is dated early February 2026 — before the subsequent 12-month surge in the stock, so the "haven't participated yet" framing is now partly stale (TER is +302% over twelve months). Treat it as directional support, not a live price view.
Net weighted conviction is +0.65 (single voice, skill- and recency-weighted) — enough to note, nowhere near enough to headline. Anyone underwriting TER should do so on the numbers and the cycle, which is exactly how we score it below.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 7 · Elevated | Net-cash balance sheet (net debt $53M, net-debt/EBITDA −0.14×) is a genuine cushion, but beta 1.79, a cyclical semi-cap end-market, Taiwan/OSAT concentration, and ~49× FY26E after a 3× 12-month run stack the downside. |
| Growth Quality | 7 · Strong | FY26E revenue +42% and EPS +114% (estimated), 59% gross margin, ROE 30%, ROIC 26% — but the revenue line has been lumpy and cyclical (peak $3.70B FY21 → trough → recovery), so it is not a smooth compounder. |
| Exponential Potential | 7 · High | The second derivative is positive — growth is accelerating on AI-compute/HBM test intensity — and at $58B cap there is room vs a large test + robotics TAM. Docked from higher because this is a cycle, not a secular straight line. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | AI-compute + HBM test demand runs harder and longer; robotics inflects; FY27E EPS beats to ~$12 (vs $10.17 cons) and the market keeps paying a peak-cycle ~46×. | ~$560 (+52%) |
| Base (our anchor) | Estimates roughly hit — FY26E EPS $7.46, FY27E $10.17; a cyclical grower earns a ~39× FY27E multiple as the cycle is mid-stream. | ~$400 (+8%) |
| Bear | AI-test air-pocket / digestion; a semi-cap down-leg pulls FY27E EPS toward ~$8 and the multiple de-rates to a mid-cycle ~30×. Earnings and multiple fall together. | ~$250 (−32%) |
Synthos fair value = the base case, ~$400 (+8%), with the full $250–$560 span as the honest range. Note how tight the base upside is: at today's price the reward is modest and the cyclical bear is a −32% drawdown — an asymmetry that argues for patience, not chasing. Our base sits essentially on top of the Street's $385.73 consensus (the Street high is $550, low $220 — a very wide band that reflects exactly this cyclical uncertainty). This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). TER is a cyclical grower in an accelerating phase — the classic "exponential-looking" mid-cycle:
- Forward growth: revenue CAGR FY25→FY28E ~30% ($3.19B → ~$6.98B estimated); EPS CAGR ~58% ($3.49 → ~$13.80 estimated) as operating leverage kicks in off a scaled test franchise.
- Acceleration (the 2nd derivative) is positive — for now: revenue growth +13.1% (FY25 actual) → +42.4% (FY26E) → +22.7% (FY27E) → +25.3% (FY28E) (estimated). The AI-compute/HBM test-intensity inflection is happening in real time; Q1'26 revenue $1.28B was nearly double Q1'25's $686M. But — the honest caveat that caps the score — semi-cap equipment is a cycle: TER did $3.70B in FY21, fell, and is only now re-taking that level. The 2nd derivative flips negative when the cycle rolls.
- Room to run: at $58B the cap is a fraction of LLY-scale megacaps, and the served market (advanced-node + HBM + automotive/industrial test, plus robotics optionality) is large and growing with AI compute. Room is not the binding constraint.
- Reinvestment runway: heavy, productive capex (~$224M FY25, ~5.9% of revenue) plus targeted M&A ($144M acquisitions FY25) — reinvesting into test capacity for AI-era devices.
Exponential Potential: High (7/10). The rare combination of accelerating growth + real room + net-cash funding earns a 7 — meaningfully above a decelerating megacap. It is not an 8–9 because the acceleration is cyclical, not secular: own it for the up-leg with clear eyes that the same second derivative reverses on the way down.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $3.19B, +13.1% (FY24 $2.82B, +5.4% on FY23 $2.68B). Below the FY21 peak of $3.70B — the business is cyclical, not linear.
- Quarterly trajectory (the inflection): Q1'25 $686M → Q2 $652M → Q3 $769M → Q4'25 $1.08B → Q1'26 $1.28B (+87% YoY). The step-up is the AI-test surge showing up in the print. Caveat: Q1'26's reported EPS of $2.55 and 37% net margin look elevated vs the underlying trend (unusually low D&A and non-operating items in the quarter) — treat the TTM ~$5.43 EPS / ~68× P/E as flattered; the cleaner read is the ~49× on FY26E consensus.
- Margins: gross 58.8% TTM (58.6% FY25), EBIT ~26.6% TTM, net 22.6% TTM. Solid, semi-cap-typical margins with real operating leverage as volume scales.
- Earnings: net income $554M FY25 (EPS $3.49); FY24 $542M; the cyclical peak was FY21's $1.01B (EPS $6.15) — a reminder of how much these earnings swing.
- Cash flow: operating CF $674M FY25, capex −$224M, FCF ~$450M FY25 (FCF yield ~0.8% at today's cap — thin, a function of the rich price). Buybacks were aggressive: −$702M repurchased FY25 plus ~$76M dividends.
- Balance sheet: net cash — total debt $347M vs cash & investments; net debt just $53M, net-debt/EBITDA −0.14×. Current ratio 2.1×. This is the single best line in the story: the growth is self-funded and the balance sheet takes downside risk off the table.
6. Valuation — priced in or room?
There is no way to call TER cheap: ~68× trailing EPS (flattered by a strong Q1'26), ~49× FY26E, ~36× FY27E, ~27× FY28E, EV/sales 15.2×, EV/EBITDA 52× TTM. The letter rating agrees — FMP's model scores price-to-earnings and price-to-book at 1/5 (richest possible) even while ROE/ROA score 5/5. The bull's defense is the same as every accelerating cyclical: earnings grow into the multiple — if FY26E–28E estimates hit, the forward P/E compresses from ~49× to ~27× at a flat price. The risk is that you are paying a peak-ish multiple on peak-ish (cyclical) earnings, and if the cycle rolls both compress together. A reverse read: at $369 the market is pricing continued high-30s%/20s% growth with little room for a demand stumble. Street targets (context): consensus $385.73, high $550, low $220 — the ~2.5× spread from low to high is itself the tell that this is a wide-outcome, cyclical name. Not a value buy; an accelerating-cyclical-at-a-full-price name where entry timing matters.
7. Technicals (from the tech block)
- Trend: mixed. $369 sits above the 200-DMA ($268) but below the 50-DMA ($385) — i.e. the long-term trend is up but short-term momentum has cracked. MACD +15.6 (still positive).
- Location: −23.7% off the 52-week high ($483.84) — a meaningful drawdown (max drawdown from peak −23.7%) — while still +309% off the 52-week low ($90.15). The quote-day print was −13.6%, so this is a name in an active pullback off a parabolic run.
- Momentum: RSI(14) 48 — neutral, neither oversold nor overbought. No stretched signal either way.
- Relative strength: TER +301.5% 12-mo vs SPY +20.6% and QQQ +30.3%; +18.2% 3-mo vs SPY +13.7% / QQQ +22.0% (lagging QQQ on 3-mo as it consolidates). The 12-month outperformance is enormous — which is precisely the setup that cuts both ways.
- Read: technicals say consolidating a huge run — below the 50-DMA, off 24% from the high, RSI neutral. There is no urgency to buy here; a hold of the 200-DMA (~$268) or a base-building period would be a lower-risk entry than chasing.
8. Moat & competitive position
Teradyne's moat is its position in the automated-test-equipment duopoly — it and Japan's Advantest split the leading-edge semiconductor-test market, with high switching costs (test programs, correlation data, and customer qualification lock in incumbents for years) and a large installed base pulling recurring service revenue (17% of sales). The AI-compute and HBM wave raises test intensity per device, which structurally favors the two incumbents. The robotics arm (Universal Robots, MiR) is a genuine optionality leg but has been a slower, more competitive grind. Threats: the cyclicality of chip capex, customer concentration (a handful of large foundries/OSATs, Taiwan-heavy), and Advantest's competitive push in SoC test.
Peer set (from FMP, market cap): the file's "peers" are a loose semiconductor/test basket rather than direct ATE comps — Astera Labs $70B, ASE Technology (OSAT) $92B, Keysight $54B (the closest test-and-measurement comp), Microchip $46B, ON Semi $36B, STMicro $61B, United Microelectronics (foundry) $61B, Sandisk $258B, Super Micro $18B, Wipro $20B. TER's truest competitor — Advantest — is not in this list; note that when reading the basket. Against these, TER commands a rich multiple justified only if the AI-test growth persists.
9. Management, capital allocation & guidance
- Capital allocation: shareholder-friendly and disciplined — FY25 returned ~$702M in buybacks + ~$76M dividends while funding ~$224M capex and ~$144M of M&A, all from a net-cash position. Repurchasing aggressively at these prices is a bet on the cycle continuing; watch that buyback doesn't chase a peak.
- Insider activity: the sampled window shows routine director/officer activity — CEO Gregory Smith sold 4,000 shares at $423.03 (2026-06-15, likely 10b5-1), a director sold 1,200 at $423.03, and several director stock awards (price $0) around 2026-06-25. A single small director open-market sale of 167 shares at $460 (2026-07-01). This reads as normal diversification and comp, not a cluster of alarming discretionary selling — though the sales were struck near the highs.
- Guidance: management's own forward guidance (ingested from SEC 8-K earnings releases) frames the AI-test ramp; there is no management voice in the Synthos KB for TER (kb_claim_count = 1, the single voice is external). Forward figures below are analyst consensus (FMP), labeled as estimates.
10. Catalysts & what to watch
- Next earnings: 2026-07-29 (Q2'26; Street EPS $2.04, revenue ~$1.22B). The key line: semiconductor-test bookings/backlog and AI-compute + HBM test commentary — is the surge sustaining or digesting? Note the recent beat pattern (Q1'26 actual $2.56 vs $2.11 est; Q4'25 $1.80 vs $1.38).
- AI-compute / HBM test intensity: the core driver — any sign of order digestion is the swing factor.
- Robotics (UR/MiR) inflection: the optionality leg; a real re-acceleration would broaden the story.
- Cyclical tells: book-to-bill, lead times, and foundry/OSAT capex signals from the broader semi-cap group.
- Concentration/geopolitics: Taiwan (36% of revenue) and China exposure to export-control shifts.
Thesis tripwires (what would change the call): a book-to-bill dropping below 1.0 for two consecutive quarters; AI-test order digestion language on the call; a break and hold below the 200-DMA (~$268); or FY27E estimates being cut — any of which would move this from Watch toward Avoid on valuation, or toward Buy — Tactical only after a meaningful de-rating.
11. Key risks
- Cyclicality (structural): semiconductor-test capex is boom/bust; TER's revenue fell from a $3.70B FY21 peak before this recovery. A down-leg compresses earnings and the ~49× multiple simultaneously.
- Valuation / de-rating: ~49× FY26E and 52× EV/EBITDA after a 3× 12-month run leave little margin for a demand or pricing disappointment; FCF yield is thin (~0.8%).
- Customer & geographic concentration: Taiwan 36% of FY25 revenue, Asia-dominant, foundry/OSAT-driven — a few large customers and geopolitical/export-control exposure.
- High beta: 1.79 — TER amplifies market drawdowns; position sizing must respect the volatility.
- Thin expert coverage: only 1 KB claim (Visser, conviction 65) and it predates the run — no breadth to lean on; this is a numbers-and-cycle call.
- Robotics drag: the industrial-automation segment has historically underdelivered vs its promise.
12. Verdict, position sizing & monitoring
Watch. Teradyne is a genuinely good business at the right point of a real AI-test acceleration — net-cash balance sheet, 59% gross margin, FY26E revenue +42% and EPS +114% (estimated), and support (if dated) from our highest-skill KB voice. But the stock has tripled in twelve months, trades at ~49× FY26E with a 1.79 beta in an inherently cyclical, customer-concentrated market, and our base-case fair value (~$400) is only +8% while the cyclical bear is −32%. That asymmetry, plus thin expert breadth (1 claim), argues for the watchlist, not the buy button, at today's price.
- Sizing: if owned at all, satellite-only, ≤1–2%, and preferably scaled in on cyclical pullbacks (a hold of the 200-DMA ~$268, or a base after this consolidation) rather than chased near the 50-DMA. This is not a core holding.
- What flips it to Buy — Tactical: a meaningful de-rating (say toward the low-30s× FY27E) with book-to-bill holding above 1.0 and the AI-test ramp intact — better price for the same growth.
- What flips it to Avoid: order digestion / book-to-bill < 1.0 for two quarters, or a break below the 200-DMA on cut estimates.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print (next 2026-07-29). This verdict is logged as a tracked Synthos call as of 2026-07-03 at $369.09.
- Single biggest risk: semi-cap cyclicality plus concentration — an AI-test air-pocket would hit earnings and the multiple at once.
Provenance & disclosures
- Traceability: 1 KB claim, breadth 1, top skill 2.0 (Jordi Visser), last claim 2026-02-05 — reconciled to a real
claim_id(cited inline). Fabricated conviction is structurally impossible (claim-ID reconciliation). Thin coverage is disclosed, not papered over; the verdict is fundamentals/quant-driven. - Data as-of: fundamentals 2026-03-29 (Q1'26) · estimates & prices 2026-07-02/03 · expert claim 2026-02-05. Forward figures are analyst consensus (FMP), explicitly labeled as estimates.
- Q1'26 caveat: trailing EPS/margins appear flattered by low D&A and non-operating items in the quarter; forward multiples (~49× FY26E) are the cleaner valuation read.
- Peer caveat: the FMP peer basket is a loose semiconductor list; TER's truest comp (Advantest) is not included.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").